Literature DB >> 8210228

The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort.

C Hublin1, J Kaprio, M Partinen, M Koskenvuo, K Heikkila, S Koskimies, C Guilleminault.   

Abstract

We investigated the prevalence of narcolepsy using a well-defined white population previously used for epidemiological investigations: the Finnish Twin Cohort. The Cohort consists of 13,888 monozygotic and dizygotic twin pairs born before 1958. There were 16,179 individuals who participated in the study, with a 77.3% response rate. The study methodology included a questionnaire covering sleep and alertness, the Ullanlinna Narcolepsy Scale (UNS), a scale specifically developed and tested for the study, telephone interviews, and finally, clinical evaluation, polygraphic recording, and HLA blood typing. Seventy-five subjects were selected for telephone interviews and laboratory evaluations based on data from both questionnaires. Five of them were strongly suspected of narcolepsy, but laboratory data identified only 3. All were dizygotic (fraternal) twins discordant for the disease with a negative family history and presence of DR2 DQw1 (i.e., DRw15 DQw6, new World Health Organization classification). The prevalence of narcolepsy in the Finnish population is 0.026% (95% confidence interval, 0.0-0.06). This prevalence is lower than that reported in studies performed without polygraphic recording and is close to that reported in 1945 in the black U.S. population. The tools developed to perform this study, the largest population study of its kind yet performed, can now be used for other population investigations.

Entities:  

Mesh:

Year:  1994        PMID: 8210228     DOI: 10.1002/ana.410350612

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  33 in total

Review 1.  Narcolepsy and excessive daytime sleepiness.

Authors:  Adam Zeman; Tom Britton; Neil Douglas; Andrew Hansen; Jane Hicks; Robin Howard; Andrew Meredith; Ian Smith; Gregory Stores; Sue Wilson; Zenobia Zaiwalla
Journal:  BMJ       Date:  2004-09-25

2.  Incidence of Narcolepsy in Germany.

Authors:  Doris Oberle; Ursula Drechsel-Bäuerle; Irene Schmidtmann; Geert Mayer; Brigitte Keller-Stanislawski
Journal:  Sleep       Date:  2015-10-01       Impact factor: 5.849

3.  Bruxism is associated with nicotine dependence: a nationwide Finnish twin cohort study.

Authors:  K Rintakoski; J Ahlberg; C Hublin; U Broms; P A F Madden; M Könönen; M Koskenvuo; F Lobbezoo; J Kaprio
Journal:  Nicotine Tob Res       Date:  2010-11-01       Impact factor: 4.244

4.  Narcolepsy in African Americans.

Authors:  Makoto Kawai; Ruth O'Hara; Mali Einen; Ling Lin; Emmanuel Mignot
Journal:  Sleep       Date:  2015-11-01       Impact factor: 5.849

5.  The narcoleptic syndrome.

Authors:  J D Parkes; S J Clift; M J Dahlitz; S Y Chen; G Dunn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-09       Impact factor: 10.154

6.  EEG-tomographic studies with LORETA on vigilance differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil.

Authors:  M Saletu; P Anderer; G M Saletu-Zyhlarz; M Mandl; O Arnold; J Zeitlhofer; B Saletu
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

7.  Depression: relationships to sleep paralysis and other sleep disturbances in a community sample.

Authors:  Mariana Szklo-Coxe; Terry Young; Laurel Finn; Emmanuel Mignot
Journal:  J Sleep Res       Date:  2007-09       Impact factor: 3.981

8.  Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

Authors:  K J McClellan; C M Spencer
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 9.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

Review 10.  From wakefulness to excessive sleepiness: what we know and still need to know.

Authors:  Maurice Moyses Ohayon
Journal:  Sleep Med Rev       Date:  2008-04       Impact factor: 11.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.